GeneDx Holdings (WGS) Payables (2020 - 2026)

GeneDx Holdings (WGS) has reported Payables for 7 consecutive years, with $46.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Payables rose 11.23% year-over-year to $46.6 million; the TTM figure through Mar 2026 stood at $46.6 million (up 11.23% YoY), while the FY2025 annual figure was $57.6 million, up 86.05% from the prior year.
• Payables fell to $46.6 million in Q1 2026 per WGS's latest filing, from $57.6 million in the prior quarter.
• Across five years, Payables topped out at $115.9 million in Q2 2022 and bottomed at $31.0 million in Q4 2024.
• Historically, Payables has averaged $57.3 million across 5 years, with a median of $52.0 million in 2024.
• Annual changes were most pronounced in 2022 — Payables surged 156.19% — and 2023, when it slumped 55.87%.
• GeneDx Holdings' Payables stood at $84.9 million in 2022, then tumbled by 55.87% to $37.5 million in 2023, then retreated by 17.28% to $31.0 million in 2024, then soared by 86.05% to $57.6 million in 2025, then decreased by 19.23% to $46.6 million in 2026.
• Business Quant data shows WGS's Payables at $46.6 million in Q1 2026, $57.6 million in Q4 2025, and $50.3 million in Q3 2025.